4 November 2013Europe

A changing market: Genomic Vision's IP strategy

When the Supreme Court decided earlier this year that isolated genetic material is not patent-eligible, it opened up the genetic screening market, inevitably introducing a new battleground for asserting IP rights on diagnostic technologies.

Many companies, including Ambry Genetics and Gene by Gene, started offering their own tests that could identify genetic disorders and susceptibility to certain diseases immediately after the June 13 ruling, and a series of patent infringement cases were filed among the companies soon after, as each tried to muscle in to the market.

French biotechnology company Genomic Vision offers a novel method of genome analysis. Its proprietary technology, which it calls molecular combing, allows researchers to view the genome at a high resolution and identify genetic anomalies within it.

Molecular combing is the process of stretching, or ‘combing’ single DNA molecules on to glass slides, and finding genes or specific sequences in the genome by measuring the distances between markers, which can be seen by applying fluorescence hybridisation. Genomic Vision calls it “Genomic Morse Code”.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at